Aβ and vGlut2 staining of 6-, 9-, and 12-month dLGN sections show significant plaque load and accelerated loss of retinal ganglion cell axon terminals in the 5xFAD mice. حسب Shaylah McCool (20818280)

UHPLC-MS CKO vs K5Cre results. حسب Kevin J. Mills (9270966)

الموضوعات:

Uncropped raw western blot images. حسب Kevin J. Mills (9270966)

الموضوعات:

LC-IMS-CID-MS CKO vs K5Cre results. حسب Kevin J. Mills (9270966)

الموضوعات:

Phospholipid metabolism CKO vs K5Cre Reactome. حسب Kevin J. Mills (9270966)

الموضوعات:

Localization and conditional deletion of C/EBP in SKH1 mouse epidermis. حسب Kevin J. Mills (9270966)

الموضوعات:

Lipidomic analysis of epidermis using LC-IMS-CID-MS reveals major changes in CKO// epidermis. حسب Kevin J. Mills (9270966)

الموضوعات:

Conditional deletion of C/EBP in epidermis results in downregulation of transcripts and pathways associated with lipid biosynthesis in epidermis. حسب Kevin J. Mills (9270966)

الموضوعات:

Additional loss of life expectancy and cost per life-year saved resulting from changes in colorectal cancer stage due to a 1-year diagnostic delay. حسب Hiroaki Saito (24514)

الموضوعات:

DDC for four anticoagulants from 2019 to 2023. حسب Wei Luo (80175)

الموضوعات:

Presentation 1_Decreased brain-derived neurotrophic factor expression in chronic kidney disease: integrated clinical and experimental evidence.pptx حسب Juan Chen (61123)

"…</p>Conclusion<p>This study integrated meta-analysis, murine model validation, and single-cell transcriptomic profiling to demonstrate a significant reduction of BDNF in CKD. Furthermore, renal BDNF expression decreased locally, predominantly originating from proximal tubule cells, macrophages, and podocytes, possibly epigenetically inhibited by the upregulation of lnc RNA Bdnf-as.…"

Inpatient utilization of anticoagulants from 2019 to 2023. حسب Wei Luo (80175)

الموضوعات:

Outpatient utilization of anticoagulants from 2019 to 2023. حسب Wei Luo (80175)

الموضوعات:

Utilization of anticoagulants from 2019 to 2023. حسب Wei Luo (80175)

الموضوعات:

The expenditure on anticoagulants in the period of 2019-2023(million CNY). حسب Wei Luo (80175)

الموضوعات:

Positioning errors of different algorithms on the a multi-modal and multi-scenario dataset for ground robots dataset. حسب Hongliang Zou (20707270)

الموضوعات:

Specific parameters of the test sequence in the a multi-modal and multi-scenario dataset for ground robots dataset. حسب Hongliang Zou (20707270)

الموضوعات:

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"